| Objectives By measuring the levels of endothelin-1 (ET-1), nitric oxide (NO) and prostacyclin (PGI2) in coronary circulation of patients with coronary heart disease (CHD), to investigate endothelial cells secretion of patients and the association between secretion and vessels diseased. Blood samples were taken from coronary sinus (CS) and coronary artery osium (AO).Methods 33 patients were identified with CHD by undergoing elective coronary angiography, who were found more than 50% stenosis of the luminal diameter in one of coronary arteries, and 18 patients without CHD. The blood samples were taken from CS and AO before coronary angiography. The plasma levels of ET-1 and 6-keto-PGF1α(a stable metabolite of PGI2), were measured by radioimmunoassay, and the plasma level of NO was measured by colorimetric method, based on the reaction for nitrite after enzymatic conversion of nitrate (NO3 to NO2) with the use of nitrate reductase. ET-1CS, NOCS, 6-keto-PGF1αCS standed for the plasma levels in CS, ET-1AO, NOAO, 6-keto-PGF1αAO stand for the plasma levels in AO, and ET-1CS-AO, NOCS-AO, 6-keto-PGF1αCS-AO stands for the plasma levels in coronary circulation. The 33 patients with CHD were divided into two subgroups: acute coronary syndrome (group ACS, n=25) and chronic stable angina pectoris (group CAP, n=8). Coronary stenosis extent includes the number of stenosis vessels (≥50% narrowings on all the vessels of the angiogram) and the number of occlusion vessels. Coronary endothelial injury extent score put forward by sullivan DR et al was performed depending on the coronary endothelial surface area affected by atheroma. Results Patients with CHD compared with patients without CHD1. the plasma level of ET-1CS increased significantly(53.41±9.45pg/ml vs 36.51±10.46pg/ml, p<0.0001); the plasma level of ET-1AO was no difference (35.27±6.58pg/ml vs 38.19±12.13pg/ml, p=0.43); the plasma level of ET-1CS-AO increased significantly(18.14±7.66pg/ml vs -1.67±7.43pg/ml, p<0.0001). 2. the plasma level of NOCS decreased significantly(44.28±12.37umol/ml vs 59.71±18.64umol/ml, p=0.015); the plasma level of NOAO was no difference(60.63±12.13umol/ml vs 61.14±19.27umol/ml, p=0.93); the plasma level of NOCS-AO decreased significantly(-16.35±7.69umol/ml vs -1.44±13.41umol/ml,p=0.004). 3. the plasma level of 6-keto-PGF1αCS was no difference (41.57±12.18pg/ml vs 51.86±18.57pg/ml, p=0.055); the plasma level of 6-keto-PGF1αAO was no difference(57.42±12.60pg/ml vs 52.22±20.68pg/ml, p=0.42); the plasma level of 6-keto-PGF1αCS-AO decreased significantly(-15.85±6.52 pg/ml vs -0.36±9.63 pg/ml,p<0.0001).ACS patients compared with CAP patients 1. the plasma level of ET-1CS increased significantly(57.66±8.49pg/ml vs 40.13±4.86pg/ml, p<0.0001); the plasma level of ET-1AO was no difference(36.42±7.03pg/ml vs 31.70±5.09pg/ml, p=0.15); the plasma level of ET-1CS-AO increased significantly (21.25±5.77pg/ml vs 8.43±5.81pg/ml, p=0.0002).2. the plasma level of NOCS was no difference(40.91±7.79umol/ml vs 54.84±16.57umol/ml, p=0.097); the plasma level of NOAO was no difference(59.45±10.56umol/ml vs 64.32±16.53umol/ml, p=0.47); the plasma level of NOCS-AO decreased significantly(-18.55±7.41umol/ml vs -9.48±5.81umol/ml, p=0.019).3. the plasma level of 6-keto-PGF1αCS decreased significantly (38.08±12.63pg/ml vs 52.48±8.81 pg/ml, p=0.017); the plasma level of 6-keto-PGF1αAO was no difference(55.88±13.13 pg/ml vs 62.24±11.57 pg/ml, p=0.34); the plasma level of 6-keto-PGF1αCS-AO decreased significantly(-17.80±6.65pg/ml vs -9.77±2.76pg/ml, p=0.0021).Plasma levels in CS compared with AO 1. the plasma level of ET-1CS was higher significantly than ET-1AO in patients with CHD(53.41±9.45pg/ml vs 35.27±6.58pg/ml, p<0.0001); the plasma level of NOCS was lower significantly than NOAO in patients with CHD(44.28±12.37umol/ml vs 60.63±12.13umol/ml, p<0.0001); the plasma level of 6-keto-PGF1αCS was lower significantly than 6-keto-PGF1αAO in patients with CHD(41.57±12.18pg/ml... |
PDF Full Text Request